GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Common Stock

Estrella Immunopharma (Estrella Immunopharma) Common Stock : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Common Stock?

Estrella Immunopharma's quarterly common stock stayed the same from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).


Estrella Immunopharma Common Stock Historical Data

The historical data trend for Estrella Immunopharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Common Stock Chart

Estrella Immunopharma Annual Data
Trend Jun21
Common Stock
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Estrella Immunopharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Estrella Immunopharma (Estrella Immunopharma) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines